Top Markets
#1 MON MON +2,759.42%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +44.53%
#4 eCash eCash +32.94%
#5 Siren Siren +24.14%
#6 Janction Janction +19.65%
#7 SAFEcoin SAFEcoin +17.31%
#8 PinGo PinGo +15.88%
#9 Velvet Velvet +15.84%
#10 Decred Decred +12.95%
Coin of the day
MON MON
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Classifica tra le azioni #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Prezzo delle azioni
$0.30780727
Capitalizzazione di mercato
$94.19M
Variazione (1 giorno)
-0.19%
Variazione (1 anno)
-34.73%
Paese
FR
Scambia Sensorion SA (ALSEN)

Categoria

Healthcare
Ricavi di Sensorion SA (ALSEN)
Ricavi nel Dec 2025 TTM: $2.73M
Secondo gli ultimi rapporti finanziari di Sensorion SA, i ricavi attuali dell'azienda (TTM) sono pari a $2.73M. Nel 2023, l'azienda ha registrato ricavi di $6.30M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $5.29M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Sensorion SA da 2011 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $2.73M -60.56%
2024 $6.92M 9.91%
2023 $6.30M 19.02%
2022 $5.29M 9.15%
2021 $4.85M 69.26%
2020 $2.86M 3.92%
2019 $2.76M 7.54%
2018 $2.56M 10.42%
2017 $2.32M 12,505.95%
2016 $18.41K -89.23%
2015 $171.03K -38.96%
2014 $280.18K -42.85%
2013 $490.29K 60.42%
2012 $305.63K 1,124,142.32%
2011 $27.19 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 1,906,201.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 448,772.67%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 546,366.42%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 332,560.08%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 230,302.17%
NL